Overview

Abatacept in Juvenile Dermatomyositis

Status:
Completed

Trial end date:
2021-01-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of subcutaneous abatacept in 10 patients seven years of age and older with refractory JDM.

Phase:

Phase 4

Details

Lead Sponsor:

George Washington University

Treatments:

Abatacept